Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the chronic hepatitis b market right now?

The chronic hepatitis B market has grown steadily in recent years. It will increase from $3.77 billion in 2024 to $3.94 billion in 2025, with a compound annual growth rate (CAGR) of 4.5%. Growth in the market is due to advances in antiviral therapy, government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and growing awareness.

How fast Is the chronic hepatitis b market expected to grow, and what’s its future value?

The chronic hepatitis B market is expected to reach $4.65 billion by 2029 at a CAGR of 4.2%. The growth in this market is attributed to expanding markets, rising healthcare expenditures, and improved diagnostic screening. Key trends include a shift toward curative therapies, partnerships, and a focus on patient-centric care.

Get your chronic hepatitis b market report here!

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

What are the leading drivers of growth in the chronic hepatitis b market?

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market. Hepatitis B is a viral liver infection, particularly prevalent in low- and middle-income countries due to low vaccination coverage. Increasing infection rates are driving demand for diagnostic tests and treatments. According to the Centers for Disease Control and Prevention, improving vaccination coverage and treatment access could prevent millions of infections and deaths by 2050. The rising incidence of hepatitis B is propelling the chronic hepatitis B virus market.

What are the key segments defining the chronic hepatitis b market?

The chronic hepatitis B market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

Who are the key players steering the development of the chronic hepatitis b market?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

What emerging trends are influencing the growth of the chronic hepatitis b market?

Companies in the chronic hepatitis B market are focusing on advancing antiviral therapies to treat resistant viral infections. For example, in February 2024, UK-based GSK received FDA Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide aimed at treating chronic hepatitis B. Bepirovirsen targets and degrades the RNA of the hepatitis B virus, showing promising results in Phase IIb trials by reducing hepatitis B surface antigen levels and achieving sustained viral suppression.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112

Which regions are most influential in expanding the chronic hepatitis b market?

North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Kidney Disease Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Chronic Disease Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: